Get started
Author

PH Brown

Observed names: P Brown, P.D. Brown
Institutions: Brigham and Women's Hospital, National Institutes of Health, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Alabama, Baylor College of Medicine, Columbia University Irving Medical Center, Tel Aviv Sourasky Medical Center, Sheba Medical Center, Moffitt Cancer Center, GlaxoSmithKline (United States), Dana-Farber Cancer Institute, National Cancer Institute, Weill Cornell Medical Center
Observed institutions: Brigham and Women's Hospital, National Institutes of Health, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Alabama, Baylor College of Medicine, University of Michigan, Columbia University Irving Medical Center, Tel Aviv Sourasky Medical Center, Sheba Medical Center, Moffitt Cancer Center, GlaxoSmithKline (United States), Dana-Farber Cancer Institute, National Cancer Institute, Weill Cornell Medical Center
OpenAlex ID: A5103648927
Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes
2013 · MD Burstein, A Tsimelzon, et al. · Cancer Research · 3
Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy
2019 · MS Trivedi, G Samimi, et al. · Cancer Research · 2
Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab
2016 · B Lim, S Jackson, et al. · Cancer Research · 1
Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ
2019 · PS Thomas, A Contreras, et al. · Cancer Research
Abstract P3-07-07: Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer
2017 · D Zhao, J Zhao, et al. · Cancer Research
Abstract P6-04-04: Maternal embryonic leucine zipper kinase (MELK) is a novel radiosensitizing and therapeutic target and is independently prognostic in triple-negative breast cancer
2013 · C Speers, M Liu, et al. · Cancer Research
PD03-03: Identification of Transcription Factors Critical for the Growth of Basal Breast Cancer.
2011 · JH Shepherd, A Mazumdar, et al. · Cancer Research
Effect of proteinase inhibition on breast cancer cell, invasion
1993 · P.S. Stonelake, P.D. Brown, et al. · The Breast
Works count: 8
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type